ILIAS PAPADIMITRIOU

Dr. ILIAS PAPADIMITRIOU

First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloníki, Kentrikí Makedonía, Greece
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NSNikolaos Sideris
Nikolaos Sideris
EPEleni Paschou
Eleni Paschou
KBKaterina Bakirtzi
Katerina Bakirtzi
DKDimitra Kiritsi
Dimitra Kiritsi
IPILIAS PAPADIMITRIOU
ILIAS PAPADIMITRIOU
EVEfstratios Vakirlis
Efstratios Vakirlis
Atopic dermatitis (AD) is a chronic inflammatory dermatosis with periods of exacerbation and remissions. AD is characterized by intense, persistent pruritus and heterogeneity in clinical symptomatology and severity. Therapeutic goals include the amelioration of cutaneous eruptions, diminishing relapses and eventually the disease burden. To date, topical corticosteroids (TCS) and calcineurin inhibitors (TCI) have yet been deemed the mainstay of topical treatments in AD management. Nevertheless, despite their indisputable efficiency, TCS and TCI are not indicated for continuous long-term use given their safety profile. While research in AD has concentrated predominantly on systemic therapies, more than 30 novel topical compounds are under development. The existing data appear encouraging, with some regimens that are already FDA-approved (ruxolitinib was the most recent in September 2021) and several pharmaceutical pipeline products for mild-to-moderate AD that are in an advanced stage of development, such as tapinarof, difamilast and roflumilast. Larger, long-term studies are still required to evaluate the efficacy and safety of these novel compounds in the long run and weigh their advantages over present treatments. In this review, we aim to provide an overview of the latest knowledge about AD topical treatments, echoing upcoming research trends.

9 May 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
IPILIAS PAPADIMITRIOU
ILIAS PAPADIMITRIOU
EVEfstratios Vakirlis
Efstratios Vakirlis
ESElena Sotiriou
Elena Sotiriou
KBKaterina Bakirtzi
Katerina Bakirtzi
Aimilios LallasAimilios Lallas
Aimilios Lallas
DIDΙmΙtrios Ioannides
DΙmΙtrios Ioannides
Sebaceous neoplasms describe a group of tumors with sebaceous differentiation commonly seen in lesions located primarily in the face and neck. The majority of these lesions are benign, while malignant neoplasms with sebaceous differentiation are uncommon. Sebaceous tumors present a strong association with the Muir–Torre Syndrome. Patients suspected with this syndrome should undergo neoplasm excision, followed by histopathologic and additional immunohistochemistry and genetics examinations. Clinical and dermoscopic features of the sebaceous neoplasms, as well as management procedures collected from the literature analysis regarding sebaceous carcinoma, sebaceoma/sebaceous adenoma, and sebaceous hyperplasia are described in the current review. A special note is made for describing the Muir–Torre Syndrome in patients presenting multiple sebaceous tumors.

19 December 2021 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
ESElena Sotiriou
Elena Sotiriou
KBK. Bakirtzi
K. Bakirtzi
IPILIAS PAPADIMITRIOU
ILIAS PAPADIMITRIOU
ATAikaterini Tsentemeidou
Aikaterini Tsentemeidou
PEP. Eftychidou
P. Eftychidou
EVE. Vakirlis
E. Vakirlis

20 August 2020 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
KBKaterina Bakirtzi
Katerina Bakirtzi
ESElena Sotiriou
Elena Sotiriou
IPILIAS PAPADIMITRIOU
ILIAS PAPADIMITRIOU
NSNikolaos Sideris
Nikolaos Sideris
EVEfstratios Vakirlis
Efstratios Vakirlis
DIDΙmΙtrios Ioannides
DΙmΙtrios Ioannides
Objective: The increasing number of elderly psoriatic patients presents a challenge for dermatologists. Biologicals and small-molecule inhibitors in the general population have demonstrated a sufficient efficacy and safety profile; yet, studies about their use in the geriatric population are lacking. In this study, we evaluated the efficacy and safety of biological and apremilast among psoriatic patients ≥65 years old. Materials and Methods: Clinical records of patients over 65 years old receiving biological drugs or apremilast were retrospectively reviewed. Efficacy was evaluated using Psoriasis Area and Severity Index (PASI) score at treatment onset and weeks 12, 24, 52 and 3 years. Adverse events were also recorded. Results: A total of 154 patients with a mean age of 70.7 ± 6.3 years-old were included in our study. Secukinumab, ustekinumab and brodalumab showed fast-acting results, while the sustained efficacy of secukinumab, ustekinumab, infliximab, adalimumab and brodalumab was also notable. Overall, 30 out of 154 (19.5%) patients reported side effects. Lower respiratory system infections (n = 6; 3.9%) and hepatic enzyme elevation (n = 6; 3.9%) were the most frequently observed events. Conclusions: Biologicals and apremilast demonstrate adequate efficacy in elderly psoriatic patients. Incidence and severity of reported adverse events were similar to those reported among patients of younger age in relevant clinical studies.

20 February 2021 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
ESElena Sotiriou
Elena Sotiriou
KBK. Bakirtzi
K. Bakirtzi
IPILIAS PAPADIMITRIOU
ILIAS PAPADIMITRIOU
EPE. Paschou
E. Paschou
EVEfstratios Vakirlis
Efstratios Vakirlis
DIDΙmΙtrios Ioannides
DΙmΙtrios Ioannides
Psoriasis (Ps) is a chronic, immune‐mediated skin disease with systemic involvement. Therapeutic advancements in its management have considerably improved disease activity and quality of life, and reduced hospitalization rates. Nevertheless, prolonged immunosuppression in psoriatic patients may increase their susceptibility to opportunistic infections.

1 October 2022 in Dermatology Practical & Conceptual
Verified
Journal Article
Open access
PDF file
ATAikaterini Tsentemeidou
Aikaterini Tsentemeidou
ESElena Sotiriou
Elena Sotiriou
NSNikolaos Sideris
Nikolaos Sideris
KBKaterina Bakirtzi
Katerina Bakirtzi
IPILIAS PAPADIMITRIOU
ILIAS PAPADIMITRIOU
EVEfstratios Vakirlis
Efstratios Vakirlis
Introduction: Patients with serious comorbidities are traditionally excluded from clinical trials. Apremilast is not contraindicated in active infections, malignancy and serious hepatic or renal impairment, but real-life data is needed to support this recommendation. Objectives: The aim of this paper is to present our personal as well as literature-sourced real-world evidenced on apremilast use in psoriasis patients with serious baseline comorbidities. Methods: A case-series and systematic literature review were performed. The psoriasis archives of a tertiary-care hospital, four electronic databases (MEDLINE, ScienceDirect, Cochrane Library, Google scholar) and other sources were searched (2014 – July 2021). Identified records were considered eligible, if they reported on the use of apremilast monotherapy in psoriasis patients with chronic infections, history of malignancy, serious liver, renal, psychiatric, or other disease(s). Results: At least 841 psoriasis patients with serious baseline diseases received apremilast. Only 3 cases of cancer progression and no infection reactivations or worsening of other diseases were documented. No increased frequency / severity of adverse events or reduced drug efficacy were noted. Main limitations of this study are the exclusion of a few reports due to inappropriately documented data and the fact that at least some patients might have been counted more than once. Conclusions: Apremilast is a safe and adequately efficacious option for psoriasis that cannot be treated / is challenging to treat with classic systemic agents and/or biologics.